Hence, in the current study, we developed a highly specific and potent small-molecule inhibitor of extracellular CTSD, referred to as CTD-002 (IC50 = 28 nM) in order to investigate its efficacy in treating NAFLD. The gene discussed is CTSD; the disease is metabolic dysfunction-associated steatotic liver disease.